Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

2.07
-0.0400-1.90%
Post-market: 2.070.00000.00%19:59 EST
Volume:116.56K
Turnover:245.78K
Market Cap:18.61M
PE:-1.09
High:2.18
Open:2.18
Low:2.04
Close:2.11
52wk High:7.95
52wk Low:1.98
Shares:8.99M
Float Shares:6.92M
Volume Ratio:0.91
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9054
EPS(LYR):-2.2184
ROE:-335.45%
ROA:-49.76%
PB:7.35
PE(LYR):-0.93

Loading ...

Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital

Reuters
·
Dec 06

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 03

Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges

TIPRANKS
·
Nov 22

Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift

TIPRANKS
·
Nov 20

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

Reuters
·
Nov 20

Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

Reuters
·
Nov 20

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

TIPRANKS
·
Nov 20

BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million

Reuters
·
Nov 20

Vivos Therapeutics Inc - Qtrly Net Loss per Share Basic and Diluted $0.49

THOMSON REUTERS
·
Nov 20

Vivos Therapeutics Q3 Gross Profit USD 3.937 Million

THOMSON REUTERS
·
Nov 20

Vivos Therapeutics Inc - Revenue $6.8 Mln in Q3 2025

THOMSON REUTERS
·
Nov 20

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

THOMSON REUTERS
·
Nov 20

Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate

Benzinga
·
Nov 20

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

GlobeNewswire
·
Nov 19

Vivos Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 17

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Nov 17

Vivos Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7

THOMSON REUTERS
·
Nov 17

Vivos Therapeutics Delays Q3 Report Amid Acquisition

TIPRANKS
·
Nov 15

BRIEF-Vivos Therapeutics Files For Non-Timely 10-Q With US SEC

Reuters
·
Nov 15

Vivos Therapeutics Inc -Anticipates That Its Revenue Increased by Over 50% for Three Months Ended September 30

THOMSON REUTERS
·
Nov 15